Lung Cancer Clinical Trial
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Summary
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
Full Description
Preliminary signals of clinical activity of ganetespib as a single agent have been observed in NSCLC. A novel approach to treatment of NSCLC is the combination of Hsp90 inhibitors, such as ganetespib, and taxanes. Such combinations have shown potential for synergy in preclinical and clinical evaluations with other Hsp90 inhibitors. Preclinical studies with ganetespib and taxanes have indicated that the combination of these drugs was more effective than either drug alone at inducing cell death, and an ongoing phase 1 study indicates that the combination is well tolerated and warrants systematic evaluation in a larger study.
Eligibility Criteria
Inclusion Criteria:
confirmed diagnosis of NSCLC
Stage IIIB or IV NSCLC
ECOG Performance Status 0 or 1
Prior therapy defined as 1 prior systemic therapy for advanced disease
measurable disease
Radiologic evidence of disease progression following most recent prior treatment.
Adequate hematologic, hepatic, renal function
Exclusion Criteria:
Active or untreated CNS metastases
Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
Serious cardiac illness or medical conditions
Pregnant or lactating women
Uncontrolled intercurrent illness
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 52 Locations for this study
Tucson Arizona, 85715, United States
Santa Monica California, 90404, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60637, United States
Boston Massachusetts, 02215, United States
Winston-Salem North Carolina, 27103, United States
Kettering Ohio, 45429, United States
Portland Oregon, 97227, United States
Brussels , 1200, Belgium
Jette , 1090, Belgium
Yvoir , 5530, Belgium
Banja Luka , 78000, Bosnia and Herzegovina
Mostar , 88000, Bosnia and Herzegovina
Sarajevo , 71000, Bosnia and Herzegovina
Sarajevo , 71000, Bosnia and Herzegovina
Tuzla , 75000, Bosnia and Herzegovina
Hamilton , L8V 5, Canada
Montreal , H3A 1, Canada
Montreal , H3G 1, Canada
Ottawa , K1H 8, Canada
Pula , 52100, Croatia
Split , 21000, Croatia
Zagreb , 10000, Croatia
Prague , 180 0, Czech Republic
Halle , 06120, Germany
Hamburg , 22045, Germany
Mainz , 55131, Germany
Mannheim , 68167, Germany
Offenbach , 63069, Germany
Krakow , 31-11, Poland
Olsztyn , 10-35, Poland
Prabuty , 82-55, Poland
Szczecin , 70-89, Poland
Cluj - Napoca , 40001, Romania
Cluj - Napoca , 40005, Romania
Craiova , 20038, Romania
Suceava , 72023, Romania
Kazan , 42002, Russian Federation
Moscow , 10522, Russian Federation
Moscow , 11547, Russian Federation
Saint-Petersburg , 19407, Russian Federation
Saint-Petersburg , 19775, Russian Federation
Sochi , 35405, Russian Federation
Voronezh , 39400, Russian Federation
Belgrade , 11000, Serbia
Sremska Kamenica , 21204, Serbia
Badalona , 08916, Spain
Barcelona , 08035, Spain
Madrid , 28040, Spain
Leicester , LE2 7, United Kingdom
London , SE1 9, United Kingdom
London , SW3 6, United Kingdom
Sutton , SM2 5, United Kingdom
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.